Leflunomide is immunomodulator drugs with applications in managing rheumatoid arthritis. In this study, four new analogs (4A-D) A771726, active metabolites of Leflunomide were synthesized and examined in vitro for their immunomodulation activities by examining the proliferation of human lymphocytes and determining the concentration of interferon-gamma cytokines in human lymphocyte cell culture.
For this purpose, 5 x 10 (4) human lymphocyte cells are incubated at 37 degrees C within 5% CO (2) with phytohemagglutinin and one analog (concentration of 1-100 mm), negative control or cyclosporine (0.1 mm). The effects of compounds on lymphocyte proliferation and interferon-gamma production are determined by the MTT test and immunosorben test related to enzymes. Our results show that the four compounds of the dependent proliferation of lymphocytes are pressed.
In addition, these compounds at several concentrations reduce the production of interferon-gamma which is an indicator of the immune response. In general, the most powerful analog is 4b with an amida link (x = NH) and the weakest analog is 4A with esters (x = o). 4A compound has a little similarity with the active metabolit of Leflunomide which has amide relationships. In this study, four new compounds were synthesized which showed a fairly large immunosuppressive effect that deserved further investigation.
Complete Combined Inhibition and CD14 ABOLISH E. Cytokine Synthesis, Kemokin and Coli-induced growth in all human blood.
Relative Complementary Role and CD14 in the synthesis of cytokines induced by E. coli in the overall human blood model in vitro examined. All freshly lepirudin-anticoagulation blood is incubated with E. coli for 2 hours. Monoclonal antibodies or C5A receptor antagonists are used to block complement. Inflammatory mediators (n = 27) are measured by multiplex technology, selected cytokine mRNA with real time PCR, and CD11b, oxidative burst and phagocytosis with the flow of cytometry. E. coli significantly increased 18 out of 27 inflammatory mediators, including proinflammatory cytokines (TNF-Alpha, IL-6, Inf-Gamma and IL-1beta), Kemokin (IL-8, MCP-1, MIP-1Alpha, MIP-1beta , Eotaxin and IP-10), growth factor (VEGF, FGF-BASIC, G-CSF and GM-CSF) and other interleukin (IL-9, IL-15 and IL-17).
In particular, the increase in all mediators was abolished by the combined inhibition of CD14 and complementary using anti-C2 and anti-factor in combination, while the relative effects of inhibition of complement and CD14 varied. In comparison, C5A and anti-CD14 receptor antagonists in combination reduce cytokine synthesis is less efficient. The real time PCR analysis confirms that cytokine synthesis is blocked at the level of the MRNA. Similarly, E. CD11b is induced by CD11B up-regulation, oxidative explosion and phagocytosis is completely hampered by CD14, anti-C2 and anti-factor D in combination after 2-hour incubation. In conclusion, the inhibition of complementary combined using anti-C2, anti-factor D and CD14 almost completely inhibits the inflammatory response induced by E. coli. Therefore a combined approach can be a new treatment regimen in gram-negative sepsis.
Antibodies anti-CD25 affect the synthesis pattern of cytokines of human dendritic cells and reduce their ability to prime allogenic t cells.
Anti-CD25 monoclonal antibodies are widely used in clinical transplants to prevent acute refusal allograft. Although the effect on T lymphocytes has been studied extensively, the impact on human dendritic cells (DC) has never been reported. Furthermore, the IL-2 role in the DC function has not been fully explained. In this study, we confirmed that the stimulation of DC monocyte-human derivative with LP greatly induces CD25 expression and that DC maturity of LPS also states the beta chain and Gamma IL-2R.
We also show that adding monoclonal antibodies anti-CD25 for LPS that induce decreased IL-12, IL-1, TNF-Alpha, IL-6, and IFN-gamma production and an increase in IL-10 synthesis by DC compared to stimulation. with LPS only. Furthermore, we show that this modification reduces the priming capability of DC helper and polarized alllimun response to Th2. Conversely, minoclonal antibodies anti-CD25 which are humble do not affect CD86, CD80, CD83, HLADR, or CD40 regulations which are induced in LPS stimulation. Taken together, this study revealed several effects previously not recognized by anti-CD25 monoclonal antibodies in DC which could contribute to their clinical efficacy. In addition, this study also explained the role of IL-2 in human DC activation.
The anti-CD25 treatment of human dendritic cells modulates both of their cytokine synthesis profiles and its capacity to activate allogeneic T cells: potential tolerogenic effects.
Recently, attention has focused on the role of dendritic cells (DCS) in the promotion of peripheral tolerance. Currently it is believed that the state of the DCS maturation / activation may be a control point for the induction of graft tolerance through modification of cell activation T. We have observed the expression of IL-2 receptor gene, and IL-2 with reverse polymerase transcriptase reaction (RT-PCR) In DC human lysate after bacterial stimulation. It has been shown in this study IL-2R Alpha (CD25) expression on human DCS on LPS activation.
 IL-10 |
|
MAB-606020011 |
Antagene |
0.1mg |
EUR 260 |
IL-10 |
|
MBS8577808-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
IL-10 |
|
MBS8577808-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
IL-10 |
|
MBS8577808-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
IL-10 |
|
MBS8577808-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
IL-10 |
|
PA1354-M |
Antagene |
100μg |
EUR 290 |
|
Description: Polyclonal Antibodies Conjugated to Magnetic Beads |
IL-10 |
|
PA1354-S |
Antagene |
100μg |
EUR 290 |
|
Description: Polyclonal Antibodies Conjugated to Sepharose Beads |
 IL-10/Interleukin-10 |
|
E21-697 |
EnoGene |
10ug |
EUR 225 |
|
|
|
Description: Recombinant Mouse Interleukin-10 is produced by our E.coli expression system and the target gene encoding Ser19-Ser178 is expressed. |
) Interleukin-10 (IL-10) |
|
MBS343058-001mg |
MyBiosource |
0.01mg |
EUR 275 |
Interleukin-10 (IL-10) |
|
MBS343058-01mg |
MyBiosource |
0.1mg |
EUR 710 |
Interleukin-10 (IL-10) |
|
MBS343058-1mg |
MyBiosource |
1mg |
EUR 3220 |
Interleukin-10 (IL-10) |
|
MBS343058-5x1mg |
MyBiosource |
5x1mg |
EUR 14325 |
) Interleukin 10 (IL-10) |
|
MBS340189-10mg |
MyBiosource |
10mg |
EUR 800 |
Interleukin 10 (IL-10) |
|
MBS340189-5x10mg |
MyBiosource |
5x10mg |
EUR 3435 |
Interleukin-10 (IL-10) |
|
MBS590015-192Wells |
MyBiosource |
192Wells |
EUR 995 |
Interleukin-10 (IL-10) |
|
MBS590015-3x192Wells |
MyBiosource |
3x192Wells |
EUR 2315 |
Interleukin-10 (IL-10) |
|
MBS590015-96Wells |
MyBiosource |
96Wells |
EUR 660 |
Interleukin-10 (IL-10) |
|
MBS592473-01mg |
MyBiosource |
0.1mg |
EUR 365 |
Interleukin-10 (IL-10) |
|
MBS592473-05mg |
MyBiosource |
0.5mg |
EUR 545 |
Interleukin-10 (IL-10) |
|
MBS592473-5x05mg |
MyBiosource |
5x0.5mg |
EUR 2205 |
IL-10/Interleukin-10 |
|
MBS8532904-001mg |
MyBiosource |
0.01mg |
EUR 305 |
IL-10/Interleukin-10 |
|
MBS8532904-5x001mg |
MyBiosource |
5x0.01mg |
EUR 1220 |
Interleukin-10 (IL-10) |
|
THP-0233 |
Creative BioMart |
1 vial |
EUR 3198.4 |
|
|
|
Description: Protein |
 IL-10 Peptide |
|
43-526P |
ProSci |
0.1 mg |
EUR 405.6 |
 IL-10 Antibody |
|
6638-100 |
Biovision |
each |
EUR 418.8 |
IL-10 Antibody |
|
6638-30T |
Biovision |
each |
EUR 175.2 |
IL-10 Antibody |
|
10-2898 |
Fitzgerald |
250 ug |
EUR 410 |
|
|
|
Description: Purified anti-Human IL-10 Antibody |
IL-10 Antibody |
|
38-312 |
ProSci |
0.5 mg |
EUR 325 |
IL-10 Antibody |
|
C30001-100ul |
Assay Biotech |
100μl |
EUR 217 |
|
Description: IL-10 Rabbit Polyclonal Antibody |
IL-10 Antibody |
|
C30001-50ul |
Assay Biotech |
50μl |
EUR 143.5 |
|
Description: IL-10 Rabbit Polyclonal Antibody |
 IL-10，Swine |
|
E34M007S |
EnoGene |
5 μg |
EUR 295 |
 IL-10，Mouse |
|
E34M010M |
EnoGene |
5 μg |
EUR 155 |
 IL-10， Human |
|
E34M012H |
EnoGene |
5 μg |
EUR 155 |
 His-IL-10 |
|
E13-019-1 |
EnoGene |
10μg |
EUR 85 |
|
Description: N/A |
His-IL-10 |
|
E13-019-2 |
EnoGene |
50μg |
EUR 350 |
|
Description: N/A |
IL-10 Antibody |
|
E10-20011 |
EnoGene |
100μg/100μl |
EUR 225 |
|
Description: Available in various conjugation types. |
 IL-10 antibody |
|
E39-04211 |
EnoGene |
100ug/100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
 Human IL-10 |
|
MBS691639-0002mg |
MyBiosource |
0.002mg |
EUR 300 |
Human IL-10 |
|
MBS691639-5x001mg |
MyBiosource |
5x0.01mg |
EUR 1725 |
 Mouse IL-10 |
|
MBS691868-0002mg |
MyBiosource |
0.002mg |
EUR 300 |
Mouse IL-10 |
|
MBS691868-5x001mg |
MyBiosource |
5x0.01mg |
EUR 1725 |
 Rat IL-10 |
|
MBS692111-5x001mg |
MyBiosource |
5x0.01mg |
EUR 1725 |
IL-10 Antibody |
|
MBS850057-01mg |
MyBiosource |
0.1mg |
EUR 305 |
IL-10 Antibody |
|
MBS850057-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
IL-10 Antibody |
|
MBS850057-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
IL-10 Antibody |
|
MBS850057-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
IL-10 Antibody |
|
MBS850057-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
 IL-10, Human |
|
MBS8575169-0005mg |
MyBiosource |
0.005mg |
EUR 245 |
IL-10, Human |
|
MBS8575169-5x0005mg |
MyBiosource |
5x0.005mg |
EUR 940 |
 IL-10, Mouse |
|
MBS8575337-0005mg |
MyBiosource |
0.005mg |
EUR 245 |
IL-10, Mouse |
|
MBS8575337-5x0005mg |
MyBiosource |
5x0.005mg |
EUR 940 |
 IL-10, Swine |
|
MBS8575427-0005mg |
MyBiosource |
0.005mg |
EUR 370 |
IL-10, Swine |
|
MBS8575427-5x0005mg |
MyBiosource |
5x0.005mg |
EUR 1520 |
 Antibody) Interleukin 10 (IL-10) Antibody |
|
abx234211-100g |
Abbexa |
100 µg |
EUR 350 |
Interleukin 10 (IL-10) Antibody |
|
abx234211-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
Interleukin 10 (IL-10) Antibody |
|
abx234212-100g |
Abbexa |
100 µg |
EUR 350 |
Interleukin 10 (IL-10) Antibody |
|
abx234212-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
Interleukin 10 (IL-10) Antibody |
|
abx432852-100g |
Abbexa |
100 µg |
EUR 250 |
Interleukin 10 (IL-10) Antibody |
|
abx432852-200ul |
Abbexa |
200 ul |
EUR 343.2 |
|
|
 Rat) Interleukin-10 (IL-10) Rat |
|
GWB-51A291 |
GenWay Biotech |
0.01 mg |
Ask for price |
|
|
 IL-10/Interleukin-10, Antibody |
|
GWB-9B391B |
GenWay Biotech |
1 ml |
Ask for price |
 Mouse) Interleukin-10 (IL-10) Mouse |
|
GWB-92B4DF |
GenWay Biotech |
0.01 mg |
Ask for price |
 Human) Interleukin-10 (IL-10) Human |
|
GWB-849240 |
GenWay Biotech |
0.01 mg |
Ask for price |
 (AP)) Interleukin 10 (Il-10) (AP) |
|
MBS6482919-01mL |
MyBiosource |
0.1mL |
EUR 1115 |
Interleukin 10 (Il-10) (AP) |
|
MBS6482919-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4875 |
 (APC)) Interleukin 10 (Il-10) (APC) |
|
MBS6482920-01mL |
MyBiosource |
0.1mL |
EUR 1115 |
Interleukin 10 (Il-10) (APC) |
|
MBS6482920-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4875 |
 (Biotin)) Interleukin 10 (Il-10) (Biotin) |
|
MBS6482921-01mL |
MyBiosource |
0.1mL |
EUR 1115 |
Interleukin 10 (Il-10) (Biotin) |
|
MBS6482921-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4875 |
 (FITC)) Interleukin 10 (Il-10) (FITC) |
|
MBS6482922-01mL |
MyBiosource |
0.1mL |
EUR 1115 |
Interleukin 10 (Il-10) (FITC) |
|
MBS6482922-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4875 |
 (HRP)) Interleukin 10 (Il-10) (HRP) |
|
MBS6482923-01mL |
MyBiosource |
0.1mL |
EUR 1115 |
Interleukin 10 (Il-10) (HRP) |
|
MBS6482923-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4875 |
 (PE)) Interleukin 10 (Il-10) (PE) |
|
MBS6482929-01mL |
MyBiosource |
0.1mL |
EUR 1115 |
Interleukin 10 (Il-10) (PE) |
|
MBS6482929-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4875 |
 (AP)) Interleukin 10 (IL-10) (AP) |
|
MBS6482930-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Interleukin 10 (IL-10) (AP) |
|
MBS6482930-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
 (APC)) Interleukin 10 (IL-10) (APC) |
|
MBS6482931-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Interleukin 10 (IL-10) (APC) |
|
MBS6482931-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
 (Biotin)) Interleukin 10 (IL-10) (Biotin) |
|
MBS6482932-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Interleukin 10 (IL-10) (Biotin) |
|
MBS6482932-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
 (FITC)) Interleukin 10 (IL-10) (FITC) |
|
MBS6482933-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Interleukin 10 (IL-10) (FITC) |
|
MBS6482933-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
 (HRP)) Interleukin 10 (IL-10) (HRP) |
|
MBS6482934-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Interleukin 10 (IL-10) (HRP) |
|
MBS6482934-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
 (PE)) Interleukin 10 (IL-10) (PE) |
|
MBS6482940-01mL |
MyBiosource |
0.1mL |
EUR 1100 |
Interleukin 10 (IL-10) (PE) |
|
MBS6482940-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4810 |
 IL-10, Interleukin-10, human |
|
RC212-21 |
Bio Basic |
2ug |
EUR 125.26 |
|
|
 IL-10, Interleukin-10, rat |
|
RC252-21 |
Bio Basic |
2ug |
EUR 125.26 |
|
|
 10 x 96) human IL-10 / IL-4 (without plate) 10 x 96 |
|
M874022010 |
Tecan Benelux |
1 unit |
EUR 1957.04 |
human IL-10 / IL-4 (without plate) 10 x 96 |
|
M874030010 |
Tecan Benelux |
1 unit |
EUR 1480.71 |
 10 x 96) human IL-10 / IL-2 (without plate) 10 x 96 |
|
M874050010 |
Tecan Benelux |
1 unit |
EUR 1480.71 |
human IL-10 / IL-2 (without plate) 10 x 96 |
|
M874052010 |
Tecan Benelux |
1 unit |
EUR 1957.04 |
) IL-10 Secreting Dendritic Cell Line (MuTu DC1940-IL-10) |
|
T8053 |
ABM |
1x10^6 cells / 1.0 ml |
Ask for price |
ELISA Kit) Human High sensitive IL-10(HS IL-10)ELISA Kit |
|
YLA4321HU-48T |
Shanghai YL Biotech |
48T |
Ask for price |
Human High sensitive IL-10(HS IL-10)ELISA Kit |
|
YLA4321HU-96T |
Shanghai YL Biotech |
96T |
Ask for price |
) human IL-10 / IL-4 (without plate) |
|
M874022001 |
Tecan Benelux |
1 unit |
EUR 244.37 |
human IL-10 / IL-4 (without plate) |
|
M874030001 |
Tecan Benelux |
1 unit |
EUR 266.67 |
) human IL-10 / IL-2 (without plate) |
|
M874050001 |
Tecan Benelux |
1 unit |
EUR 266.67 |
human IL-10 / IL-2 (without plate) |
|
M874052001 |
Tecan Benelux |
1 unit |
EUR 244.37 |
 Antibody) Human Interleukin-10 (IL-10) Antibody |
|
13109-05011 |
AssayPro |
150 ug |
EUR 175 |
 Recombinant Mouse Interleukin-10/IL-10 |
|
C697-10ug |
Novoprotein |
10ug |
EUR 242.4 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
Recombinant Mouse Interleukin-10/IL-10 |
|
C697-1mg |
Novoprotein |
1mg |
EUR 2983.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
Recombinant Mouse Interleukin-10/IL-10 |
|
C697-500ug |
Novoprotein |
500ug |
EUR 1935.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
DCS is distinguished from monocytes exposed anti-CD25 during maturation, anti-CD25 treatment affects the ability of human DCS to induce CD4 + cell proliferation in responding to alloantigens, maintaining endocytic, anti-CD25 treated capacity to produce low level IL-12 and IFN and high levels of IL-10. All these characteristics show that DC can be used in cellular therapy both to induce allograft tolerance (anti-CD25 treated DCS) or to restore immunity to tumors (IL-2 DCRE).
